Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of batifiban injection in acute coronary syndrome patients undergoing PCI
ChiCTR2400092377Phase 3Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevifibatide in acute coronary syndrome (ACS), unstable angina, myocardial infarction (MI) and 1 more (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: 30-day composite ischemic/procedural endpoint after PCI. Started Nov 2024; status: completed.
02
Drugs
bevifibatide
03
Conditions
acute coronary syndrome (ACS)unstable anginamyocardial infarction (MI)Non-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on ChiCTR2400092377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092377.